Anti-Osteoporotic Medication-Related Jaw Osteonecrosis: A Descriptive Analysis of the European EudraVigilance Database

Sofia Ferreira Azevedo; Cláudia Pinto Oliveira; Ana Rita Prata; Inês Cunha; Anabela Barcelos

doi:10.20344/amp.23257

Anti-Osteoporotic Medication-Related Jaw Osteonecrosis: A Descriptive Analysis of the European EudraVigilance Database

Authors

Sofia Ferreira Azevedo Rheumatology Department. Unidade Local de Saúde da Região de Aveiro. Aveiro. & Egas Moniz Health Alliance. Aveiro. https://orcid.org/0000-0002-1786-7925
Cláudia Pinto Oliveira Rheumatology Department. Unidade Local de Saúde da Região de Aveiro. Aveiro. & Egas Moniz Health Alliance. Aveiro. https://orcid.org/0000-0002-6824-3688
Ana Rita Prata Rheumatology Department. Unidade Local de Saúde da Região de Aveiro. Aveiro. & Egas Moniz Health Alliance. Aveiro. https://orcid.org/0000-0002-9432-2216
Inês Cunha Rheumatology Department. Unidade Local de Saúde da Região de Aveiro. Aveiro. & Egas Moniz Health Alliance. Aveiro.
Anabela Barcelos Rheumatology Department. Unidade Local de Saúde da Região de Aveiro. Aveiro. & EpiDoc Unit. NOVA Medical School. Universidade NOVA de Lisboa. Lisbon. & Comprehensive Health Research Center. Universidade NOVA de Lisboa. Lisbon. https://orcid.org/0000-0002-4116-8964

DOI:

https://doi.org/10.20344/amp.23257

Keywords:

Adverse Drug Reaction Reporting Systems, Bisphosphonate-Associated Osteonecrosis of the Jaw/etiology, Bone Density Conservation Agents/adverse effects, Osteoporosis/drug therapy, Pharmacovigilance

Downloads

Download data is not yet available.

References

Singer A, McClung MR, Tran O, Morrow CD, Goldstein S, Kagan R, et al. Treatment rates and healthcare costs of patients with fragility fracture by site of care: a real-world data analysis. Arch Osteoporos. 2023;18:42.

Barcelos A, Gonçalves J, Mateus C, Canhão H, Rodrigues AM. Costs of incident non-hip osteoporosis-related fractures in postmenopausal women from a payer perspective. Osteoporos Int. 2023;34:2111-9.

National Osteoporosis Guideline Group. Clinical guideline for the prevention and treatment of osteoporosis. 2024. [cited 2025 Oct 04]. Available from: https://www.nogg.org.uk/sites/nogg/download/NOGG-Guideline-2024.pdf?v4.

Mbese Z, Aderibigbe BA. Bisphosphonate-based conjugates and derivatives as potential therapeutic agents in osteoporosis, bone cancer and metastatic bone cancer. Int J Mol Sci. 2021;22:6869.

Anastasilakis AD, Pepe J, Napoli N, Palermo A, Magopoulos C, Khan AA, et al. Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS. J Clin Endocrinol Metab. 2022;107:1441-60.

European Medicines Agency. EudraVigilance – European database of suspected adverse drug reaction reports. 2024. [cited 2025 Oct 04]. Available from: https://www.adrreports.eu.

Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72:905-8.

Kawahara M, Kuroshima S, Sawase T. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review. Int J Implant Dent. 2021;7:47.

Downloads

Published

2025-11-03

How to Cite

Ferreira Azevedo S, Pinto Oliveira C, Prata AR, Cunha I, Barcelos A. Anti-Osteoporotic Medication-Related Jaw Osteonecrosis: A Descriptive Analysis of the European EudraVigilance Database. Acta Med Port [Internet]. 2025 Nov. 3 [cited 2025 Dec. 8];38(11):750-2. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/23257

Download Citation

Issue

Vol. 38 No. 11 (2025): November

Section

Letters to the Editor

License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.

It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.

Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.

After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.